Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C

Abstract

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3… (More)
DOI: 10.1155/2016/3852126

Topics

2 Figures and Tables

Slides referencing similar topics